



# UnitedHealth Group, Inc. (UNH)

Updated January 21<sup>st</sup>, 2021 by Josh Arnold

## Key Metrics

|                             |       |                                            |       |                                  |                       |
|-----------------------------|-------|--------------------------------------------|-------|----------------------------------|-----------------------|
| <b>Current Price:</b>       | \$351 | <b>5 Year CAGR Estimate:</b>               | 10.0% | <b>Market Cap:</b>               | \$333 B               |
| <b>Fair Value Price:</b>    | \$328 | <b>5 Year Growth Estimate:</b>             | 10.0% | <b>Ex-Dividend Date:</b>         | 03/15/21 <sup>1</sup> |
| <b>% Fair Value:</b>        | 107%  | <b>5 Year Valuation Multiple Estimate:</b> | -1.4% | <b>Dividend Payment Date:</b>    | 03/29/21 <sup>2</sup> |
| <b>Dividend Yield:</b>      | 1.4%  | <b>5 Year Price Target</b>                 | \$528 | <b>Years Of Dividend Growth:</b> | 11                    |
| <b>Dividend Risk Score:</b> | B     | <b>Retirement Suitability Score:</b>       | C     | <b>Last Dividend Increase:</b>   | 15.7%                 |

## Overview & Current Events

UnitedHealth dates back to 1974 when Charter Med was founded by a group of health care professionals looking for ways to expand healthcare options for consumers. UnitedHealth has certainly done that in the decades since and now offers global healthcare services to tens of millions of people via a wide array of products. The company has two major reporting segments: UnitedHealth and Optum. The former provides global healthcare benefits to individuals, employers and Medicare/Medicaid beneficiaries. The Optum segment is a services business that seeks to lower healthcare costs and optimize outcomes for its customers. UnitedHealth's market capitalization is \$333 billion, and it produces about \$278 billion in revenue annually, making it one of the largest companies in America by that measure.

UnitedHealth reported fourth quarter and full-year earnings on January 20<sup>th</sup>, 2021 with results once again coming in ahead of expectations. Revenue was up nearly 8% year-over-year and beat consensus by nearly half a billion dollars at \$65.5 billion. Premiums revenue was up 6.2% to \$50.6 billion, while Products revenue rose 14% to \$8.7 billion, and Services revenue was up 10.2% to \$5.8 billion. Investment and other income was up fractionally to \$445 million. By business line, Optum once again proved the growth driver, as has been the case for some time. That segment saw revenue soar 20% to \$35.9 billion, while UnitedHealthcare was up 4.3% to \$50.3 billion.

The company's medical care ratio for the full-year was just 79.1%, down from 82.5% in 2019 based upon the return of the health insurance tax, which was offset by the massively disrupted care patterns that took place due to COVID-19-driven office closures and lack of patient demand. We expect the company's medical care ratio to begin to rebound to more normalized levels in 2021.

Earnings came to \$16.88 for the full year, up from \$15.11 in the prior year as the health insurance tax and certain operational investments offset some of the gains from the medical care ratio moving lower. The company guided for adjusted earnings of \$17.75 to \$18.25 per share for 2021, but given its chronic tendency to underestimate, we initiate 2021 at \$18.20 in earnings-per-share.

## Growth on a Per-Share Basis

| Year                      | 2011   | 2012   | 2013   | 2014   | 2015   | 2016   | 2017    | 2018    | 2019    | 2020    | 2021           | 2026           |
|---------------------------|--------|--------|--------|--------|--------|--------|---------|---------|---------|---------|----------------|----------------|
| <b>EPS</b>                | \$4.73 | \$5.28 | \$5.50 | \$5.70 | \$6.01 | \$8.05 | \$10.07 | \$12.19 | \$15.11 | \$16.88 | <b>\$18.20</b> | <b>\$29.31</b> |
| <b>DPS</b>                | \$0.61 | \$0.80 | \$1.05 | \$1.41 | \$1.88 | \$2.38 | \$2.88  | \$3.45  | \$4.14  | \$4.83  | <b>\$5.00</b>  | <b>\$9.63</b>  |
| <b>Shares<sup>3</sup></b> | 1,070  | 1,019  | 988    | 954    | 953    | 952    | 969     | 968     | 962     | 961     | <b>960</b>     | <b>955</b>     |

We see forward earnings-per-share growth of 10% annually as UnitedHealth continues to boost margins and generate revenue growth. We note that the sheer size of UnitedHealth makes it more difficult to grow over time, but Optum continues to be outstanding in pushing the top line higher. We do not believe the company's very impressive run of earnings-per-share growth is ending by any means, but a slight reduction in growth expectations over the next five years seems prudent. Margin expansion is also playing a meaningful part in the earnings growth story, as evidenced again in

<sup>1</sup> Estimated date

<sup>2</sup> Estimated date

<sup>3</sup> Share count in millions

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# UnitedHealth Group, Inc. (UNH)

Updated January 21<sup>st</sup>, 2021 by Josh Arnold

2020. We don't believe the long-term outlook for UnitedHealth has been altered in any way by the COVID-19 situation, and that 2021 should see a return to normalized growth trends.

## Valuation Analysis

| Year      | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | Now         | 2026        |
|-----------|------|------|------|------|------|------|------|------|------|------|-------------|-------------|
| Avg. P/E  | 9.8  | 10.4 | 11.9 | 14.7 | 19.4 | 16.8 | 18.4 | 20.4 | 16.5 | 17.8 | <b>19.3</b> | <b>18.0</b> |
| Avg. Yld. | 1.3% | 1.5% | 1.6% | 1.7% | 1.6% | 1.8% | 1.5% | 1.4% | 1.7% | 1.6% | <b>1.4%</b> | <b>1.8%</b> |

UnitedHealth's price-to-earnings multiple is nearly identical to where it was at the time of our last update at 19.3. The business has posted continuously strong earnings growth rates and as such, investors have assigned a high-teens multiple in recent years. With shares trading above our fair value estimate of 18 times earnings, this could drive a small headwind to annual total returns. We see the yield rising over time as UnitedHealth has proven its commitment to increasing the dividend at meaningful rates. With the most recent dividend increase, UnitedHealth boosted its payout by 16% on top of the 20% increase prior to that.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

| Year   | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021       | 2026       |
|--------|------|------|------|------|------|------|------|------|------|------|------------|------------|
| Payout | 13%  | 15%  | 19%  | 24%  | 31%  | 29%  | 28%  | 28%  | 27%  | 29%  | <b>28%</b> | <b>33%</b> |


As mentioned, we see the payout ratio rising over time, as UnitedHealth's dividend is ultra-safe today. At less than one-third of earnings, UnitedHealth has tremendous flexibility in terms of returning capital to shareholders. Its outstanding earnings growth should only strengthen this over time.

UnitedHealth's competitive advantage is in its gargantuan scale as well as its deeply entrenched customers with high switching costs. Like a utility, health and wellness providers have high switching costs, accruing significant benefits to incumbents like UnitedHealth. It is also quite resistant to recessions as its services are necessities in most cases.

## Final Thoughts & Recommendation

We see UnitedHealth as a premier growth stock that is trading only somewhat above its fair value. Its strong growth forecast makes it attractive to growth investors, while its high rate of dividend growth makes it attractive for those seeking longer term income. We forecast total annual returns of 10.0%, consisting of the current 1.4% yield, 10% earnings growth and a small headwind from the valuation. UnitedHealth is an attractive long-term story offering high rates of earnings and dividend growth. Given the total return outlook at 10% annually, we reiterate the stock at a buy.

## Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# UnitedHealth Group, Inc. (UNH)

Updated January 21<sup>st</sup>, 2021 by Josh Arnold

## Income Statement Metrics

| Year             | 2010  | 2011   | 2012   | 2013   | 2014   | 2015   | 2016   | 2017   | 2018   | 2019   |
|------------------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Revenue (\$B)    | 93.55 | 101.21 | 109.94 | 121.74 | 129.70 | 156.40 | 184.01 | 200.14 | 224.87 | 240.27 |
| Gross Profit     | 22589 | 24491  | 27189  | 29194  | 32236  | 36316  | 42558  | 45988  | 52470  | 55712  |
| Gross Margin     | 24.1% | 24.2%  | 24.7%  | 24.0%  | 24.9%  | 23.2%  | 23.1%  | 23.0%  | 23.3%  | 23.2%  |
| SG&A Exp.        | 14270 | 15557  | 17306  | 18941  | 21263  | 24312  | 28401  | 29557  | 34074  | ---    |
| D&A Exp.         | 1064  | 1124   | 1309   | 1375   | 1478   | 1693   | 2055   | 2245   | 2428   | 2720   |
| Operating Profit | 7255  | 7810   | 8574   | 8878   | 9495   | 10311  | 12102  | 14186  | 15968  | 17799  |
| Op. Margin       | 7.8%  | 7.7%   | 7.8%   | 7.3%   | 7.3%   | 6.6%   | 6.6%   | 7.1%   | 7.1%   | 7.4%   |
| Net Profit       | 4634  | 5142   | 5526   | 5625   | 5619   | 5813   | 7017   | 10558  | 11986  | 13839  |
| Net Margin       | 5.0%  | 5.1%   | 5.0%   | 4.6%   | 4.3%   | 3.7%   | 3.8%   | 5.3%   | 5.3%   | 5.8%   |
| Free Cash Flow   | 5395  | 5901   | 6085   | 5684   | 6526   | 8184   | 8090   | 11573  | 13650  | 16392  |
| Income Tax       | 2749  | 2817   | 3096   | 3242   | 4037   | 4363   | 4790   | 3200   | 3562   | 3742   |

## Balance Sheet Metrics

| Year               | 2010  | 2011  | 2012  | 2013  | 2014  | 2015   | 2016   | 2017   | 2018   | 2019   |
|--------------------|-------|-------|-------|-------|-------|--------|--------|--------|--------|--------|
| Total Assets (\$B) | 63.06 | 67.89 | 80.89 | 81.88 | 86.38 | 111.25 | 122.81 | 139.06 | 152.22 | 173.89 |
| Cash & Equivalents | 9123  | 9429  | 8406  | 7276  | 7495  | 10923  | 10430  | 11981  | 10866  | 10980  |
| Acc. Receivable    | 2061  | 2294  | 2709  | 3052  | 4252  | 6523   | 8152   | 9568   | 11388  | 11822  |
| Goodwill & Int.    | 25655 | 26770 | 35968 | 35448 | 36609 | 52844  | 56125  | 63045  | 68235  | 76010  |
| Total Liabilities  | 37238 | 39597 | 49707 | 49733 | 53928 | 77529  | 84633  | 89225  | 97902  | 113453 |
| Accounts Payable   | 9220  | 16652 | 17988 | 19033 | 21287 | 26324  | 29752  | 33051  | 36596  | 21690  |
| Long-Term Debt     | 13503 | 11638 | 16754 | 16860 | 17406 | 31965  | 32970  | 31692  | 36554  | 40678  |
| Total Equity       | 25825 | 28292 | 31178 | 32149 | 32454 | 33830  | 38274  | 47776  | 51696  | 60436  |
| D/E Ratio          | 0.52  | 0.41  | 0.54  | 0.52  | 0.54  | 0.94   | 0.86   | 0.66   | 0.71   | 0.67   |

## Profitability & Per Share Metrics

| Year             | 2010  | 2011  | 2012   | 2013   | 2014   | 2015   | 2016   | 2017   | 2018   | 2019   |
|------------------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|
| Return on Assets | 7.6%  | 7.9%  | 7.4%   | 6.9%   | 6.7%   | 5.9%   | 6.0%   | 8.1%   | 8.2%   | 8.5%   |
| Return on Equity | 18.7% | 19.0% | 18.6%  | 17.8%  | 17.4%  | 17.5%  | 19.5%  | 24.5%  | 24.1%  | 24.7%  |
| ROIC             | 12.1% | 13.0% | 12.6%  | 11.6%  | 11.4%  | 10.1%  | 10.3%  | 13.8%  | 13.9%  | 14.4%  |
| Shares Out.      | 1,086 | 1,070 | 1,019  | 988    | 954    | 953    | 952    | 969    | 968    | 962    |
| Revenue/Share    | 82.71 | 93.11 | 105.10 | 119.01 | 131.54 | 161.73 | 190.10 | 203.18 | 228.76 | 248.73 |
| FCF/Share        | 4.77  | 5.43  | 5.82   | 5.56   | 6.62   | 8.46   | 8.36   | 11.75  | 13.89  | 16.97  |

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

## Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.